LYVE1 and neoplasm: In this experiment, 86% to 94% of differentiated GFP+ cells were positive for Lyve-1, Ter-119 and CD3e immediately prior to transfer (Fig 4 and S2 Fig), but only 10% of tumor-residing GFP+ cells displayed this profile 4 weeks after transfer (Fig 7).